Open AccessFive Decades of Enucleations for Uveal Melanoma in One Center: More Tumors with High Risk Factors, No Improvement in Survival over Time
Author(s) -
Christine D M Roelofsen,
Annemijn P A Wierenga,
Sjoerd G. van Duinen,
Robert M. Verdijk,
J.C. Bleeker,
Marina Marinković,
Grégorius P. M. Luyten,
Martine J. Jager
Publication year - 2020
Publication title -
ocular oncology and pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.444
H-Index - 10
eISSN - 2296-4681
pISSN - 2296-4657
DOI - 10.1159/000509918
Subject(s) - medicine , enucleation , gastroenterology , surgery
Background: In order to improve medical care for uveal melanoma (UM) patients, we need to monitor disease and survival to guide our research efforts. We analyzed the data of UM patients who underwent an enucleation at the Leiden University Medical Center over the last five decades and investigated trends in patient and tumor characteristics and survival. Methods: Data were collected from charts and pathology reports from all patients who underwent an enucleation for UM between 1973 and 2019 ( n = 1,212), of which 1,066 were primary enucleations; data were analyzed according to five time periods: 1973–1979 ( n = 209), 1980–1989 ( n = 148), 1990–1999 ( n = 174), 2000–2009 ( n = 280), and 2010–2019 ( n = 401). Results: Over time, mean patient age at the time of enucleation for UM increased from 54.9 to 64.7 years ( p < 0.001), more tumors showed histopathological involvement of the ciliary body ( p < 0.001), and were classified in a high TNM/AJCC class ( p < 0.001). Overall, the 5- and 10-year UM-related survival rates were 0.68 and 0.59, respectively. Over time, survival showed no change in patients with tumors in AJCC stages I or III, with recently a slightly worse survival in stage II UM ( p = 0.02). Conclusion: Between 1973 and 2019, we found similar rates of UM-related survival following enucleation, although we noticed a strong increase in more unfavorable patient and tumor characteristics over time, such as an older age and larger tumor size. The lack of improvement indicates that more research should take place to develop adjuvant treatments to prevent metastases and efficient treatments once metastases develop.